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Abstract
Objective: The aim of this study was to characterize changes in free triiodothyronine (fT3), free thyroxine (fT4)
and thyroid-stimulating hormone (TSH) during the follicular and luteal phase and during subsequent early pregnancy
in individual women.
Method: TPOAb negative women with a viable pregnancy (n=49) had fT3, fT4 and TSH measured longitudinally
in serum samples at baseline/non-pregnant (gestation week 0), ovulation (gestation week 2), mid-luteal phase
(gestation week 3) and twice weekly from gestation weeks 4 to 6.5. Patient groups received in their conception cycle
either no medication (n=13), low ovarian stimulation, (n=17) or controlled ovarian hyperstimulation (COH) for IVF
treatment (n=19).
Results: Women receiving COH had a transient drop in TSH at the time of ovulation followed by a peak at mid-
luteal (p=0.024). Levels of fT3 and fT4 at each gestation week were not significantly different between the treatment
groups, whereas TSH levels were significantly higher at all gestation weeks (p=0.036) in the COH group compared
to the natural and low stimulation groups. There were significant changes in thyroid function once pregnancy was
established (gestation week 4) through to gestation week 6.5, with a gradual decrease in serum fT3 (r=-0.104,
p=0.030) and TSH (r=-0.123 p=0.031), whilst fT4 levels remained constant. 3 women (6.1%) had TSH levels >4.0
mU/L during their pregnancy although these were isolated measurements.
Conclusion: Thyroid hormones in individual women did not remain constant but showed discrete changes. TSH
was significantly lower at time of ovulation in women who received high doses of ovarian stimulation medication for
IVF, and was higher throughout pregnancy than for the other groups. Serum fT3 and TSH decreased significantly
during early pregnancy irrespective of medication given in the conception cycle.
Keywords: Thyroid-stimulating hormone; Free triiodothyronine;
Free thyroxine; Pregnancy
Introduction
Maternal thyroid hormones play a critical role in fetal development,
particularly in early pregnancy, since the fetal thyroid gland does not
become functional until the second trimester. TSH levels are known to
decrease during the first trimester, correlated with an increase in
human chorionic gonadotropin (hCG) [1]. The decrease in TSH is
most likely due to a weak stimulatory effect of hCG on TSH receptors
on the thyroid. The most commonly accepted reason for TSH reducing
slightly in the first trimester is that there is homology between the
alpha subunits of both TSH and hCG [2]. As such, hCG can act on
TSH receptors at the thyroid and stimulate them, thereby increasing
T4 and T3. This feed back to the hypothalamus, decreasing TRH, TSH
and, in turn, decreasing T3 and T4 as part of the natural negative
feedback loop. TSH is therefore lowest when hCG is at its highest
because hCG rises until 8-10 weeks of pregnancy and then plateaus
and starts falling when TSH starts recovering. Such changes during
pregnancy have resulted in the need for pregnancy-stage specific
reference ranges to prevent the misdiagnosis of disease [3-5].
Thyroid autoimmunity is characterized by the presence of
antithyroid antibodies. Of particular interest is the marker antithyroid
peroxidase which is responsible for thyroid hormone synthesis [6].
Approximately 10-20% of euthyroid women (having TSH within a
defined normal range) are positive for thyroid peroxidase antibody
(TPOAb) [7,8], of which 16% will develop a TSH that exceeds 4.0
mlU/L by the end of the third trimester. About 50% of TPOAb positive
women will develop postpartum thyroiditis, which is a consequence of
the immunological changes that occur during pregnancy [9]. There is
evidence that women who test positive for TPOAb during pregnancy
tend to have higher TSH levels, which may indicate a slight
impairment of thyroid function [10-13]. Numerous studies have
reported that TPOAb positive women have an increased risk of
miscarriage [14-19] as well as an increased risk of preterm birth [20].
Therefore, TPOAb is a strong risk factor for thyroid dysfunction both
during and after pregnancy [21].
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The clinical classification of thyroid dysfunction has been debated
for over a decade. Only recently has a general consensus been reached
that the upper limit for TSH in pregnancy is lower than in non-
pregnant adults. A generally accepted upper reference interval for TSH
in the first trimester of pregnancy is an upper limit of 2.5 mIU/L [9].
However, universally accepted reference ranges for thyroid function
tests during pregnancy are still needed. Until then, laboratories need to
adapt their own assay-dependent, gestational age specific and
population specific reference ranges for thyroid testing in pregnant
women [7].
Adequate treatment of thyroid conditions in pregnancy, particularly
during early gestation greatly minimises pregnancy risks and
complications, resulting in significantly improved outcomes and
highlighting the need for correct diagnosis. Despite this need for
detection of thyroid dysfunction in pregnancy, most studies that report
on changes in thyroid function tests in pregnancy are cross-sectional in
design, using blood obtained from pathology laboratories undertaking
first trimester screening [3] or retrospective cohorts where the small
changes in individual women were not the focus [22]. Whilst providing
practical guidance on the interpretation of clinical screening tests and
pregnancy outcomes in relation to thyroid status [23], large cohorts do
not describe the changes that may occur during early pregnancy
(especially prior to gestation week 12), nor are there established
reference intervals at this time during pregnancy. The focus of our
longitudinal study was to document changes in the concentration of
thyroid hormones, namely fT3, fT4 and TSH during the follicular and
luteal phase and during subsequent early pregnancy in individual
women. We collected blood in 49 women in both the conception cycle
and then the subsequent period of pregnancy monitoring until the
time of a fetal heart on ultrasound scan at 6.5 weeks gestation.
Materials and Methods
Patients
Ethical approval to undertake this research project was given by the
Joondalup Health Campus Human Research Ethics Committee (Ethics
Approval Number 1414) and the Edith Cowan University Human
Research Ethics Committee (Ethics Approval Number 12077). Women
who attended Fertility North for fertility treatment were recruited after
evidence of a positive pregnancy blood test 14 days after ovulation,
namely if the serum hCG concentration was >25 IU/mL measured on
a Centaur XP automated analyser (Siemens Healthcare Pty. Ltd.,
Bayswater, Victoria 3153, Australia). The 49 recruited pregnant women
conceived either in an unstimulated monitoring ‘natural’ cycle (n=13),
after low dose FSH stimulation with either intercourse (n=10) or intra-
uterine insemination (n=7) or a high dose FSH controlled ovarian
stimulation cycle (n=19) for subsequent in-vitro fertilisation (IVF)
treatment. All women were non-smokers, iodine replete (reside in
Western Australia), BMI <35 and TPOAb negative. One woman was
excluded from the study that tested positive for TPOAb.
Sample collection and processing
All dates were according to the gestational age relative to Day 1 of
the cycle in which conception occurred. Blood samples were collected
from each woman at the following times:
a) Conception cycle. Blood was available for 49 women at baseline/
non-pregnant (day 2-3), week 2 (around the time of ovulation) and
week 3 (mid-luteal phase).
b) Pregnancy monitoring. Blood samples were collected in all 49
women from week 4, at the time of the serum positive pregnancy test,
twice weekly until fetal heartbeat was seen by ultrasound
(approximately week 6.5).
The blood samples were stored frozen at -20°C until assayed for
thyroid hormones.
Thyroid assays and quality control
The precision of the Siemen’s thyroid hormone reagents (fT3, fT4
and TSH) were analysed using both commercial QC material (Bio-rad
Lyphochek Immunoassay Plus Control 1, 2 and 3, Irvine, CA) and
pooled patient serum. The within-assay coefficient of variation,
determined by analyzing 20 replicates of 3 serum pools for fT3 (4.5-5.5
pmol/L), fT4 (15.0-17.5 pmol/L) and TSH (1.8-2.6 pmol/L), was ≤
3.1%, ≤ 5.2 and ≤ 2.8 respectively. The concentrations of each pooled
sample were close to the average levels of thyroid hormones typically
found in each patient. Quality control material (three levels) provided
by the manufacturer were also included in each assay. The blood
samples from each woman were thawed at room temperature and
analyzed together on the same day in one batch to eliminate between-
assay variability for each woman.
Statistical analysis
Analyses were performed using IBM SPSS Statistics Version 23. The
relationships between each of the thyroid hormones during pregnancy
were analyzed using bivariate correlations (2-tailed, Spearman) to
determine the correlation coefficient (r) and p-value (significance).
General linear models and repeated measures ANOVA were used to
measure the relationships between thyroid hormones, gestation week
and hCG. Differences were statistically significant when p<0.05.
Concentrations for TSH were log-transformed and the geometric
mean and standard deviation were obtained from the anti-log values.
Results
fT3 levels before and during early pregnancy
The fT3 concentrations between each of the three treatment groups
were not significantly different (p=0.065) before or during early
pregnancy (gestation weeks 2 to 6.5), with mean concentrations of 4.65
± 0.12 pmol/L in the natural group, 4.52 ± 0.15 pmol/L in the low
ovarian stimulation group and 4.64 ± 0.09 pmol/L in the controlled
ovarian hyperstimulation group. There were no significant differences
observed between gestation weeks 2-6.5 for all patients (p=0.343),
although there was a gradual decreasing trend seen in early pregnancy
(gestation weeks 4-6.5) (r=-0.104, p=0.030).
ft4 levels before and during early pregnancy
The fT4 concentrations between each of the three treatment groups
were not significantly different (p=0.336) before or during early
pregnancy (gestation weeks 2 to 6.5), with mean concentrations of 15.0
± 0.2 pmol/L in the natural group, 14.4 ± 0.2 pmol/L in the low ovarian
stimulation group and 15.0 ± 0.2 pmol/L in the controlled ovarian
hyperstimulation group. There were no significant differences observed
for all patients during their conception cycle or during early pregnancy
(gestation weeks 2-6.5) (p=0.123).
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TSH levels before and during early pregnancy
TSH levels were significantly higher between gestation weeks 0-6.5
in the controlled ovarian hyperstimulation group (p=0.036), with a
mean of 1.84 ± 0.06 mIU/L compared to only 1.27 ± 0.05 mIU/L in the
natural group and 1.30 ± 0.06 mIU/L in the low stimulation group.
Pairwise comparisons of TSH concentrations within the controlled
hyperstimulation group revealed a significant difference (p=0.024)
between the time of ovulation (gestation week 2), with a mean
concentration of 1.49 mIU/L, compared to a peak level of 1.97 mIU/L
at mid-luteal phase (gestation week 3). There was also a trend of lower
TSH levels at time of ovulation within the natural and low stimulation
groups, however non-significant (p=0.106 and p=0.052 respectively).
When combining all patient groups together, there was a strong
significant difference between gestation weeks 2 and 3 (p=0.001) and
gestation weeks 2 and 4 (p=0.008). Once pregnancy was established
(gestation week 4), the mean TSH concentration decreased
significantly during early pregnancy (up to gestation week 6.5)
(r=-0.123 p=0.031). 19 patients (38.8%) in this study at one or more
points during their pregnancy had a TSH measurement >2.5 mU/L
and of these patients, 3 (6.1%) also had TSH >4.0 mU/L, although
these were isolated measurements.
Relationship between thyroid hormones and hCG
fT3, fT4 and TSH were all positively correlated with each other
(p<0.005). However, all significant correlations were very weak (r<0.3)
and unlikely to be a direct consequence of an interaction between the
hormones, with very weak effect sizes - the strongest being between
fT3 and fT4 with only about 8.4% (r2). fT3 and TSH levels were
negatively correlated with levels of hCG (Table 1) during early
pregnancy (p=0.005 and p=0.001 respectively).
Gestation
Week
Mean
(mU/mL) Sem
95% CI
Lower Upper
4 251.9 30.1 191.6 312.2
4.5 1384.1 182.2 1019.2 1749
5 5187.5 565.4 4054.8 6320.2
5.5 13852.5 1167.7 11513.3 16191.6
6 29686.4 2183.5 25312.4 34060.4
6.5 53844.4 3525.2 46782.6 60906.2
Table 1: Concentrations of QhCG during early pregnancy.
Thyroid distribution in conception cycles and early
pregnancy
Serum samples from all women in the study that had viable
pregnancies (n=49) and tested negative for TPOAb (<28 U/ml) were
used to calculate levels for TSH (median and 95% CI) and fT3 and fT4
(both mean ± 1sd) between gestation weeks 2-6.5 for each of the
treatment groups (Tables 2-4). Where available, non-pregnant levels
were calculated from both screening bloods (day 2 of the menstrual
cycle taken prior to the conception cycle), or at gestation week 0 (day
2) of the conception cycle.
Sample type n TSH (mIU/L) fT3 (pmol/L) fT4 (pmol/L)
Adult reference
range
229 0.55-4.78 3.50-6.50 11.5-22.7
Non-pregnant 13 1.43 (0.56-2.87) 4.71 ± 0.35 15.7 ± 1.8
2 weeks gestation 13 1.01 (0.39-2.55) 4.61 ± 0.44 14.2 ± 2.2
3 weeks gestation 13 1.24 (0.67-2.58) 4.50 ± 0.41 15.2 ± 1.6
4 weeks gestation 13 1.10 (0.65-3.63) 4.62 ± 0.47 15.2 ± 1.3
4.5 weeks gestation 13 1.17 (0.53-2.09) 4.63 ± 0.37 15.5 ± 1.2
5 weeks gestation 13 1.09 (0.69-2.12) 4.52 ± 0.41 15.4 ± 1.5
5.5 weeks gestation 13 0.98 (0.53-2.66) 4.65 ± 0.32 15.4 ± 1.1
6 weeks gestation 12 0.95 (0.50-2.28) 4.55 ± 0.27 15.1 ± 1.3
6.5 weeks gestation 10 1.02 (0.33-2.01) 4.53 ± 0.36 15.9 ± 2.0
Table 2: Serum concentrations of TSH (median and 95% CI), fT3 and
fT4 (both mean ± 1sd) in pregnant women conceiving in a natural
menstrual cycle. The adult reference range was provided by the assay
manufacturer. TSH ranges obtained from screening bloods (usually
day 2 of the menstrual cycle) in the few months prior to conception
cycle, whilst fT3 and fT4 ranges obtained from baseline (gestation
week 0) measurements.
Sample type n TSH (mIU/L) fT3 (pmol/L) fT4 (pmol/L)
Adult reference
range
229 0.55-4.78 3.50-6.50 11.5-22.7
Non-pregnant 15 1.04 (0.47-2.39) 4.44 ± 0.69 14.4 ± 2.4
2 weeks gestation 15 0.95 (0.40-2.48) 4.71 ± 0.46 12.7 ± 2.6
3 weeks gestation 17 1.29 (0.53-3.12) 4.72 ± 0.42 14.4 ± 2.7
4 weeks gestation 17 1.59 (0.48-2.54) 4.66 ± 0.42 14.2 ± 2.3
4.5 weeks gestation 17 1.25 (0.52-2.40) 4.42 ± 0.44 14.0 ± 2.5
5 weeks gestation 17 1.31 (0.51-2.52) 4.57 ± 0.41 13.6 ± 2.2
5.5 weeks gestation 17 1.04 (0.48-2.43) 4.47 ± 0.39 14.0 ± 2.3
6 weeks gestation 16 1.01 (0.39-2.57) 4.39 ± 0.35 14.4 ± 2.2
6.5 weeks gestation 9 0.89 (0.54-2.69) 4.41 ± 0.41 15.2 ± 1.4
Table 3: Serum concentrations of TSH (median and 95% CI), fT3 and
fT4 (both mean ± 1sd) in pregnant women conceiving in a cycle with
mild ovarian stimulation. The adult reference range was provided by
the assay manufacturer. TSH ranges obtained from screening bloods
(usually day 2 of the menstrual cycle) in the few months prior to
conception cycle, whilst fT3 and fT4 ranges obtained from baseline
(gestation week 0) measurements.
Sample type n TSH (mIU/L) fT3 (pmol/L) fT4 (pmol/L)
Adult reference
range
229 0.55-4.78 3.50-6.50 11.5-22.7
Non-pregnant 19 1.76 (0.62-3.56) Not available Not available
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2 weeks gestation 19 1.49 (0.49-1.71)* 4.76 ± 0.47 14.9 ± 2.7
3 weeks gestation 19 1.97 (0.66-3.84)* 4.74 ± 0.41 15.5 ± 2.0
4 weeks gestation 19 1.81 (0.96-3.61) 4.78 ± 0.50 14.9 ± 1.8
4.5 weeks gestation 19 1.75 (0.78-3.82) 4.70 ± 0.56 15.0 ± 2.4
5 weeks gestation 19 1.94 (0.61-3.36) 4.66 ± 0.49 15.0 ± 2.5
5.5 weeks gestation 19 1.77 (0.63-3.02) 4.67 ± 0.46 15.0 ± 2.4
6 weeks gestation 19 1.66 (0.68-3.31) 4.73 ± 0.39 14.3 ± 2.2
6.5 weeks gestation 18 1.49 (0.41-2.97) 4.51 ± 0.40 14.8 ± 2.3
Table 4: Serum concentrations of TSH (median and 95% CI), fT3 and
fT4 (both mean ± 1sd) in pregnant women conceiving in an IVF cycle
with controlled ovarian hyperstimulation, and bled at different times
in their conception cycle and during early pregnancy. *denotes values
are significantly different (p<0.05). The adult reference range was
provided by the assay manufacturer. TSH ranges obtained from
screening bloods (usually day 2 of the menstrual cycle) in the few
months prior to conception cycle.
Discussion
Maternal thyroid changes during pregnancy
During the first trimester, maternal changes in thyroid hormones
are well known and the rise in hCG results in very mild and transient
increases in fT4 and fT3, which via a negative feedback, leads to a
decrease in TSH [24,25]. An increase in free T4 has been noted toward
the end of the first trimester by some authors [26], but not by all
studies [27], and it is important to note that measurement of thyroid
hormones in pregnancy is complex. Factors such as rising Thyroid
Binding Globulin (TBG) and falling albumin levels can change binding
dynamics [28] and there are unknown effects on direct free thyroid
hormone assays. Furthermore, it is known that levels of fT3 are largely
determined by peripheral de-iodination of fT4 [29,30]. Two main types
of deiodinase are found-Type I in the liver, kidney and thyroid and this
enzyme determines measured serum levels of fT3. Type II deiodinase
is found in the pituitary and may be differently regulated from Type I.
This differential regulation of the two deiodinases can explain apparent
“discrepancies” in fT4, fT3 and TSH levels. These discrepant values are
common in clinical practice and can occur in acute illness such as ‘sick
euthyroid syndrome’ [31,32] or in starvation [33], uraemia [34] or
diabetes [35].
Despite the active thyroid changes that occur in the first trimester
and the importance to fetal development, most published studies
during this time are cross-sectional and do not look at any time points
prior to gestation week 8. The current study focused on gestational
weeks 4 to 6.5, with blood sampling twice weekly in individual women
in order to establish longitudinal distribution of thyroid levels in early
pregnancy.
In this study, there were no significant changes documented in fT4
levels during the time period, with mean concentrations from
gestation week 4 to 6.5 similar to the non-pregnant concentration at
week 0. We did note however, gradual small but significant decreases in
fT3 from gestation weeks 4 to 6.5. As expected, TSH concentration
dropped significantly with gestational age, from gestation week 4
onwards. This strongly correlated with the rapid rise in hCG during
this time, which is consistent with the trend in the first trimester of
pregnancy [25]. The relationships between each of the hormones fT3,
fT4 and TSH during gestation were demonstrated to be statistically
significant. There were no significant differences between non-
pregnant (gestation week 0) and pregnant (gestation week 4) fT3, fT4
or TSH levels.
The lack of change in fT4 is not surprising as many authors note
that changes in thyroid hormones are minimal because the
compensatory decrease in TSH occurs very rapidly to re-establish
normal free thyroid hormones. The issues of the type of measurement
of fT4 in pregnancy also need to be considered and to more exactly
document changes to free T4, complex and expensive methods such as
ultrafiltration or dialysis have been proposed. However, these are not
practical for clinical practice.
The reduction in fT3 initially appeared surprising. However, when
considering the changes that occur in activity of the Type I deiodinase
in states of starvation and in diabetes these changes are not dissimilar
to those that occur in early pregnancy. Early pregnancy is a state where
fasting rapidly results in low glucose due to the high levels of insulin
and activity of lipolytic hormones. In contrast, after a meal pregnant
women are more likely to be hyperglycaemic (similar to diabetic
women) as they have higher levels of insulin but concurrent insulin
resistance. A reduction in Type I deiodinase activity may result in
reduced fT3 levels. However, in these situations, Type II deiodinase
which controls pituitary T3 levels, is not affected. As such, normal/high
levels of fT4 in the pituitary are converted normally to fT3 and this
results in reduction of TSH from the hypothalamic –pituitary axis. It is
also interesting that fT3 levels decreased in early pregnancy, a time
when women often experience nausea and/or vomiting which puts the
body in a state similar to starvation, resulting in decreased peripheral
conversion of T4 to T3.
This study showed that all thyroid markers remained positively
correlated with each other, although a very weak effect size. There is no
literature that examines the interaction between fT3, fT4 and TSH
during this early gestation period, so it is difficult to establish what are
considered expected changes in these levels. It is known that serum fT3
and fT4 levels increase slightly at 10-12 weeks when hCG is at its
highest, but remain within normal limits [36], whilst TSH
concentrations decrease, fT3 and fT4 levels also decrease later in
pregnancy when hCG starts to decline. Furthermore, the changes in
thyroid hormones that take place at different time points during
gestation are a result of complex effects that may be seen only
momentarily. Hence the gradual decrease in fT3 that was observed
during gestation weeks 4 to 6.5 is not likely to have any effect on the
pregnancy itself, especially when levels are within expected ‘normal’
limits.
Thyroid function during conception cycles
This present study observed a significant difference in TSH levels
between time of ovulation (gestation week 2) and time of conception
(gestation week 3). Another study has observed a weak association
between TSH and estradiol levels (borderline significance) which
occurs at time of ovulation in the menstrual cycle [37]. In addition,
this present study observed significantly higher TSH levels in women
who were undertaking IVF treatment. There have been a few authors
that have investigated the relationship between thyroid function and
controlled ovarian hyperstimulation (COH) in IVF cycles and show
that TSH increases significantly with a rise in oestrogen [38,39] and
elevated TSH is linked to decreased fertilisation rates in those women
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undertaking IVF treatment [37]. The reasons as to why TSH is higher
in this treatment group is uncertain, especially since these patients are
undertaking fertility treatment due to a number of various underlying
conditions (for example endometriosis, PCOS, male factor). A large
proportion of the IVF patients in this study have had difficulties
conceiving in the past and have also suffered recurrent miscarriage,
which is consistent with the study on higher TSH and fertilisation rates
[37]. A more recent study investigating IVF patients and TSH levels
following treatment reported that TSH levels peaked 1 week after the
hCG trigger (mid-luteal) [40] which is supported by the results of this
present study that showed TSH was significantly higher at the same
time point.
There were no significant differences observed in fT3 or fT4 levels
during ovulation or luteal phase in any of the treatment groups. fT4
was slightly higher (non-significant) during the mid-luteal phase
(gestation week 3) in the IVF treatment group when TSH was also at
its highest. These results are inconsistent with a previous study that
reported a significant decrease in fT4 after ovarian stimulation (the
same time point) [38]. However, the literature has shown that the
relationship between fT4 and TSH is complex and non-linear [41] and
this present longitudinal study has further contributed to our
understanding of thyroid function at various time points during the
menstrual cycle and very early pregnancy.
TSH and TPOAb in Pregnancy
There have been numerous studies that have investigated the role of
thyroid hormones in maintaining early pregnancy or in recurrent
miscarriage [42-49] and the literature suggests there is an increased
association with miscarriage and abnormal levels of thyroid hormones.
A relationship between elevated TSH serum levels and risk of
miscarriage has been reported previously [50], however rates of
subclinical hypothyroidism during pregnancy are very low, between
2-3% [51]. Other studies in women undergoing fertility treatment
cycles have reported that elevated TSH levels (above 2.5 mlU/L) do not
adversely affect clinical outcomes [22,23]. The results of this present
study showed a higher than average rate of hypothyroidism (6.1%)
(defined as TSH levels >4.0 mU/L), however the 3 patients with
elevated TSH all had successful pregnancies. The mean TSH
concentrations measured for all woman in this study were within
normal ranges during early pregnancy.
Thyroid autoantibody measurement is a common marker of
autoimmune thyroid disease, and women who test positive should be
excluded from thyroid hormone studies, as these women may have
higher TSH levels [10-13] and a greater risk of miscarriage [52]. More
importantly, inclusion of these women when calculating thyroid
reference intervals could result in falsely high values. This study
excluded 1 woman (2.0%) from the analysis as she tested positive for
TPOAb. The prevalence of 2.0% (1/50) TPOAb recorded in this study
is lower than another study that reported 5.4% of women undertaking
ART tested positive for TPOAb [53], although this was in a much
larger cohort (n=688). The TPOAb positive woman excluded from this
study had undergone an OI (low ovarian stimulation) cycle. This
woman had thyroid levels within the ‘normal’ ranges determined in
this study and was a viable pregnancy (single fetal heartbeat detected).
Interestingly, there is a known elevated risk of miscarriage with the
presence of TPOAb and this woman had a previously failed cycle and
also had PCOS, which is associated with an increased prevalence of
autoimmune thyroiditis [54,55]. This woman’s medical history was an
indicator of the association between reproductive disorders and
thyroid dysfunction.
Thyroid reference ranges in early pregnancy
A woman’s thyroid status during pregnancy is difficult to establish
without gestational age-specific reference ranges. In addition to
maternal thyroid changes during gestation [26], there are significant
differences in reference intervals between immunoassays [56-58],
highlighting the need for further research to establish reliable common
limits to correctly diagnose thyroid dysfunction in pregnancy.
There is a current paucity of literature that examines thyroid
reference ranges prior to gestation week 9, and most research is
performed even later in the first trimester. Although the number of
patients in this present study were not large enough to provide
reference ranges, the data obtained is invaluable, documenting
important thyroid distribution data and characterising changes that
occur during early pregnancy between gestation weeks 4 to 6.5.
TSH concentrations were log transformed to normalise the data
before determining appropriate concentration ranges. The median for
each gestation week in the natural and low stimulation groups fell
below 1.6 mU/L, with the high stimulation group having a median of
above 1.66 mU/L at each gestation week except week 2 (ovulation) and
week 6.5 (both 1.49 mU/L). The normal first trimester upper range
recommended by the Guidelines of the American Thyroid Association
is 2.5 mU/L [9]. 38.8% of patients in this study at one point during
their pregnancy had at least one TSH measurement >2.5 mU/L and
6.1% of patients had at least one measurement >4.0 mU/L. Elevated
TSH levels did not affect pregnancy outcome as the patients included
in this study all had viable pregnancies. Levels that are considered
“normal” during early pregnancy are constantly debated. The cut-off
point of 2.5 mU/L for TSH, particularly for women undertaking ART,
was crossed at one or more time points by a high percentage of women
in this study.
Mean thyroid hormones levels in this study did not differ between
non-pregnant (gestation week 0) and early pregnancy (gestation weeks
4 to 6.5). However, it is known that first trimester thyroid function is
different to pre-pregnancy, in particular a decrease in TSH, which is
the same trend observed in the present study. Median levels of TSH in
this study (1.37 mU/L) were higher than published levels later in the
first trimester (0.89 mU/L) [58] and (0.77 mU/L) [59] indicating that
levels of TSH would likely continue to decrease in later first trimester
weeks and therefore would end up being significantly different to non-
pregnant levels. fT4 levels between gestation weeks 4 to 6.5 reported in
this study for the natural treatment group (14.96 pmol/L) were similar
to levels reported by another study later in the first trimester (gestation
weeks 9 to 13) (15.1 pmol/L) [59]. To the best of our knowledge, fT3
data during early pregnancy has not been well documented and so the
gradual decrease that was observed in this study between gestation
weeks 4 to 6.5 is a novel finding.
In summary, this study has provided important thyroid distribution
data for a critical time in pregnancy, when the growing fetus relies on
maternal levels of thyroxine for neurocognitive development. We
established that the average non-pregnant levels of all thyroid markers
(gestation week 0) did not predict the levels during early pregnancy
(from gestation week 4 to 6.5), however there were significant
differences noted between multiple time points during conception
cycles for TSH levels. It may be helpful for clinicians to be aware that
thyroid levels may change week by week, despite all upper limits still
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falling within the “normal” range during the first trimester. It would be
useful to confirm the levels found in this study with a larger cohort and
establish references ranges. Despite the known adverse effects of
thyroid disease during pregnancy, the prevalence of the disease is low
and further research is needed on pregnancy outcomes and treatment
of women with thyroid disease.
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